Allspring Global Investments Holdings LLC Has $2.53 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,917 shares of the biopharmaceutical company's stock after selling 5,610 shares during the period. Allspring Global Investments Holdings LLC's holdings in Halozyme Therapeutics were worth $2,532,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Park Place Capital Corp raised its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 182 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares during the period. Parallel Advisors LLC grew its holdings in Halozyme Therapeutics by 12.5% in the first quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock valued at $120,000 after purchasing an additional 208 shares during the period. Finally, Baird Financial Group Inc. increased its position in Halozyme Therapeutics by 2.0% during the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 221 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded up $0.78 during trading hours on Wednesday, reaching $56.58. The company had a trading volume of 1,552,376 shares, compared to its average volume of 1,756,857. The firm has a market capitalization of $6.97 billion, a PE ratio of 15.05, a PEG ratio of 0.37 and a beta of 1.15. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13. The stock has a 50-day moving average of $55.16 and a two-hundred day moving average of $56.75. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the previous year, the firm earned $0.79 earnings per share. The business's revenue was up 35.2% on a year-over-year basis. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HALO. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Finally, Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $39,422,721.87. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the sale, the director directly owned 28,611 shares of the company's stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,497 shares of company stock valued at $2,405,284 in the last quarter. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.